Cara Therapeutics
CARA
$0.69
Share price
-5.72%
Change (1 day)
-83.80%
Change (1 year)
Categories
P/S ratio for Cara Therapeutics (CARA)
P/S ratio as of April 2024 (TTM): 1.80
According to Cara Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.79859. At the end of 2023 the company had a P/S ratio of 1.93.
P/S ratio history for Cara Therapeutics from 2014 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 1.93 | -85.99% |
| 2022 | 13.8 | -51.25% |
| 2021 | 28.3 | 406.59% |
| 2020 | 5.58 | -85.25% |
| 2019 | 37.8 | -0.84% |
| 2018 | 38.2 | -91.29% |
| 2017 | 438 | -85.13% |
| 2016 | > 1000 | 2339.11% |
| 2015 | 121 | 68.86% |
| 2014 | 71.6 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.78 | 109.91% | 🇺🇸 USA |
 Pfizer PFE | 2.46 | 36.65% | 🇺🇸 USA |
 Trevena TRVN | 2.09 | 16.25% | 🇺🇸 USA |
 Recro Pharma
REPH | N/A | N/A | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | 0.0070 | -99.61% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | 22.4 | 1,145.13% | 🇺🇸 USA |